Swiss stocks - Factors to watch on Nov 4

ZURICH Nov 4 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Wednesday:

CLARIANT (CLN.VX)

Swiss specialty chemicals maker Clariant posted a smaller third-quarter net profit of 25 million Swiss francs, ahead of forecasts even as recession sapped demand for its products.

For related news, click on [CLN.VX]

NOBEL BIOCARE (NOBN.VX)

Swiss dental implant maker Nobel Biocare more than doubled its third-quarter net profit as its cost-cutting efforts offset the continuing drop in demand, but refrained from giving an outlook.

For related news, click on [NOBN.VX]

NOVARTIS <NOVN.VX

Swiss drugmaker Novartis AG is buying a 85 percent stake in Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical for some $125 million to boost its presence in the fast growing market.

For related news, click on [NOVN.VX]

UBS (UBSN.VX)

UBS AG has taken key roles on two landmark deals to shore up British banks -- landing the Swiss bank a welcome boost in fees and prestige on the same day it shocked the market with worse-than-expected results.

For related news, click on [UBSN.VX]

ECONOMY [M-CH]

COMPANY STATEMENTS [CNR-CH]

* Private Equity Holding (PEHN.S): Half-year results as of September 30, 2009 [PEHN.S]

* Swisscom (SCMN.VX)acquires Credit Suisse subsidiary WECO [SCMN.VX]

EQUITY RESEARCH [CH-RCH]

FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:

.EX.S for all Swiss stocks

.EXSMI.S for blue chips

.EXNSMI.S for other stocks